文献速递肝病

尿液白细胞介素18与脂质运载蛋白2是肝硬化患者急性肾小管坏死的生物标志物:系统评价与Meta分析

Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-12-21

该系统评价与Meta分析纳入8项前瞻性研究共1129例肝硬化患者,评估尿白细胞介素18(IL18)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)区分急性肾小管坏死(ATN)与其他类型肾损伤及预测短期死亡的价值。结果显示,IL18区分ATN的AUC为0.88(95%CI 0.79-0.97),NGAL为0.89(95%CI 0.84-0.94);两者预测住院期间或90天内死亡的AUC均为0.76(IL18 95%CI 0.68-0.85;NGAL 95%CI 0.71-0.82)。作者认为这些生物标志物或可用于判断预后和选择治疗。

要点

  • 尿IL18区分肝硬化患者ATN与其他肾损伤的AUC为0.88。
  • 尿NGAL区分ATN与其他肾损伤的AUC为0.89。
  • 尿IL18和NGAL预测短期死亡的AUC均为0.76。

核心结论

  • 在系统评价与Meta分析中,肝硬化患者尿IL18和NGAL水平可区分ATN与其他类型肾损伤,AUC分别为0.88和0.89。
  • 尿IL18和NGAL识别短期死亡患者的AUC均为0.76。
  • 作者认为这些生物标志物或可用于判断预后和选择治疗。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Scopus、ISI Web of Knowledge及会议摘要至2015年12月31日。
  • 纳入仅评估3项及以上独立研究的生物标志物,检索词包括尿生物标志物、肝硬化、NGAL和IL18。
  • 分析8项前瞻性研究,共1129例肝硬化患者。

主要发现

  • 尿IL18区分ATN与其他类型肾损伤的AUC为0.88(95%CI 0.79-0.97)。
  • 尿NGAL区分ATN与其他类型肾损伤的AUC为0.89(95%CI 0.84-0.94)。
  • 尿IL18识别住院期间或90天内死亡(短期死亡)患者的AUC为0.76(95%CI 0.68-0.85)。
  • 尿NGAL识别短期死亡患者的AUC同为0.76(95%CI 0.71-0.82)。

关键数值与推荐

  • 采用双变量逻辑混合效应模型计算汇总灵敏度和特异度及受试者工作特征曲线下面积(AUC)。
  • 采用χ2检验评估研究间异质性。

临床怎么用

  • 作者认为这些生物标志物或可用于判断肝硬化患者预后和选择治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute kidney injury (AKI) is a common complication in patients with cirrhosis that increases mortality. The most common causes of AKI in these patients are prerenal azotemia, acute tubular necrosis (ATN), and hepatorenal syndrome; it is important to determine the etiology of AKI to select the proper treatment and predict patient outcome. Urine biomarkers could be used to differentiate between patients with ATN and functional causes of AKI. We performed a systematic review and meta-analysis of published studies to determine whether urine levels of interleukin (IL)18 and lipocalin 2 or neutrophil gelatinase-associated lipocalin (NGAL) are associated with the development of ATN in patients with cirrhosis. METHODS: We searched MEDLINE, Scopus, ISI Web of Knowledge, and conference abstracts through December 31, 2015, for studies that assessed urine biomarkers for detection of acute kidney injury in patients with cirrhosis or reported an association between urine biomarkers and all-cause mortality in these patients. We included only biomarkers assessed in 3 or more independent studies, searching for terms that included urine biomarkers, cirrhosis, NGAL, and IL18. We calculated the pooled sensitivities and specificities for detection and calculated the area under the receiver operating characteristic curve (AUC) values using a bivariate logistic mixed-effects model. We used the χ2 test to assess heterogeneity among studies. RESULTS: We analyzed data from 8 prospective studies, comprising 1129 patients with cirrhosis. We found urine levels of the markers discriminated between patients with ATN and other types of kidney impairments, with AUC values of 0.88 for IL18 (95% confidence interval [CI], 0.79-0.97) and 0.89 for NGAL (95% CI, 0.84-0.94). Urine levels of IL18 identified patients who would die in the hospital or within 90 days (short-term mortality) with an AUC value of 0.76 (95% CI, 0.68-0.85); NGAL identified these patients with the same AUC (0.76; 95% CI, 0.71-0.82). CONCLUSIONS: In a systematic review and meta-analysis, we found that urine levels of IL18 and NGAL from patients with cirrhosis discriminate between those with ATN and other types of kidney impairments, with AUC values of 0.88 and 0.89, respectively. Urine levels of IL18 and NGAL identified patients with short-term mortality with an AUC value of 0.76. These biomarkers might be used to determine prognosis and select treatments for patients with cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Puthumana J, Ariza X, Belcher JM, et al. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016. PMID: 28013112. doi:10.1016/j.cgh.2016.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。